| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expense), net | 11,967 | 16,998 | 21,939 | 17,023 |
| Net income (loss) | -3,729,128 | -1,733,517 | -1,945,573 | 661,769 |
| Deemed dividend related to warrants down round provision | - | 0 | - | - |
| Net loss attributable to noncontrolling interests | - | -166 | - | - |
| Net income (loss) attributable to common stockholders | -3,729,128 | -1,733,351 | -1,945,573 | 661,769 |
| Net income (loss) per share attributable to common stockholders, basic | -1.29 | -0.79 | -1.39 | 0.07 |
| Net income (loss) per share attributable to common stockholders, diluted | -1.29 | -0.79 | -1.39 | 0.07 |
| Weighted average common shares outstanding, basic | 2,886,059 | 2,202,299 | 1,401,144 | 9,890,390 |
| Weighted average common shares outstanding, diluted | 2,886,059 | 2,202,299 | 1,401,144 | 9,890,390 |
Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. (ENSC)